Study Evaluating Drug LY3209590 in Adults with Type 1 Diabetes (BDCP)

In by ECIR

Study Evaluating Drug LY3209590 in Adults with Type 1 Diabetes (BDCP)

  • Hidden
  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

1. Diagnosis of type 1 diabetes mellitus for at least 1 year
2. On multiple daily injections for at least 3 months
3. HbA1c between 5.6% to 9.5%
4. BMI ≤ 35 kg/m²

Exclusion Criteria

1. More than 1 emergency room visit or hospitalization due to poor glucose control within 6 months
2. Any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months
3. Have any of the following cardiovascular conditions: acute MI, NYHA Class III or IV heart failure, or stroke
4. acute or chronic hepatitis
5. eGFR < 30 ml/min/1.73 m² 6. active or untreated cancer

Back to Current Studies